Cannabics Pharmaceuticals Inc. (CNBX)

OTC Bulletin Board / Cannabics Pharmaceuticals Inc. (CNBX)

Last Post:  on 10/16/2014 1:45:53 PM | 5 Total Posts

Posted by:
qualitystocks

09/20/2014
06:16:23 AM

Cannabics Pharmaceuticals Inc. (CNBX)

Cannabics Pharmaceuticals is engaged in developing sophisticated cannabinoid-based medicines. Researchers from the cancer research, molecular biology, and pharmacology fields founded the Bethesda, Maryland-based company in 2012 and, through a research and development annex in Israel, are cultivating a pipeline of advanced, cannabinoid-based therapies. In addition, through collaborations with key medical centers in Europe, Israel, and the United States, Cannabics is now initiating a series of clinical studies to study the favorable effects of its products in diverse indications.

Cannabics develops all of its proprietary technologies in certified laboratories and licenses the use of these technologies to certified manufacturers and distributors with the appropriate licenses in their local territories. Cannabics itself does not manufacture, possess, dispense or distribute controlled substances.

Cannabics’ laboratories are developing a wide range of standardized, reproducible and easy to administer solutions around medical cannabis therapies. The company’s flagship product is Cannabics SR, a sustained-release, medical cannabis capsule designed as a pain-soothing care treatment for cancer patients. The capsule provides 10-12 hours of beneficial therapeutic effects and, as a result, patients need only be dosed once a day. The capsules are also available to patients in four increasing dosages.

Cannabics SR capsules contain a pure essence of cannabinoids obtained from carefully chosen cannabis strains while the excipient, the inactive substance that serves as the medium for the proprietary sustained-release formulation, is a certified food-grade ingredient and free of chemical substances and artificial additives.

Cannabics is committed to researching and developing progressive scientific technologies in the field of cannabinoid-based therapies. The company’s research is especially focused on:

Developing advanced routes for administering active cannabinoids;
Identifying the positive therapeutic effects of various cannabis-based compounds; and
Developing personalized cannabinoid therapies as anti-tumor vehicles.

Through such focused studies, the company’s researchers have gained indispensable knowledge on the effectiveness of a variety of cannabis strains as therapies for specific indications. Cannabics’ pharmacology team has also gained valuable knowledge and expertise on the development of superior delivery systems for active cannabinoids that offer enhanced treatment options to patients wishing to use the unique medical properties of the cannabis plant.

Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com

 

 

Login   or   Sign Up   to post a reply.

qualitystocks
9/26/2014 6:18:50 PM

Cannabics Pharmaceuticals, Inc. (CNBX) Achieves GMP Compliance, Announces Preparation of Clinical Study

Cannabics Pharmaceuticals today announced that it has attained Good Manufacturing Practices (GMP) capabilities. Additionally, the company reported it is moving toward the launch of its first clinical study of Cannabics SR capsules.

GMP regulations are designed to ensure that products are produced and controlled according to quality standards. Adhering to these practices ranks Cannabics’ products among a very limited number of medical cannabis products available in the U.S. market that are manufactured according to GMP standards.

Cannabics’ Chief Technology Officer Dr. Eyal Ballan stated, “We’re proud to announce GMP standing as we prepare for the upcoming launch of our Cannabics SR capsules. We have developed a product with incredible potential in the oncology market and aim to maintain product integrity throughout the entire manufacturing process.”

Cannabics plans to launch a number of clinical studies in leading medical centers in Israel where the company’s R&D division is strategically located. The company is on track to become one of the first and few companies to commercialize clinically tested cannabis-based products.

“Cannabics SR, our first market ready product, was developed and designed specifically as a palliative therapy for oncology patients,” commented Dr. Ballan. “We are still developing a broad pipeline of additional cannabis based products designed for various indications such as Neuropathic pain, inflammatory bowel disease, post trauma stress syndrome, CNS degenerative disorders and more. Each of these products will be tested in comprehensive and formal clinical studies to prove its efficacy and safety.”

Cannabics emphasized that its products will have a strong advantage over competing medical cannabis products in the market. In addition to the superior pharmacokinetic profile of the Cannabics SR formulations, the company will have clinical results of the efficacy and safety data collected in these formal post-marketing studies.

Cannabics intends to market Cannabics SR capsules under the current medical cannabis regulations in the United States, Europe and Israel. Based on a proprietary formulation that contains only certified food ingredients, Cannabics SR capsules will be marketed as a “cannabis-infused edible product” and will be available to certified and registered patients.

In previous observational studies, Cannabics SR capsules has been shown to provide 10-12 hours of reduced nausea and pain while promoting appetite for cancer patients. These capsules are taken only one to two times a day. Also, because they are taken orally as capsules, patients avoid the long-term harmful effects of smoking cannabis.

“Cannabics SR capsules answer a considerable unmet need to alleviate the discomforts of oncology patients without the health hazards associated with smoking cannabis for palliative purpose,” stated Dr. Ballan. “To date, more than 100 patients in Israel (most of them oncology patients) have already been treated with Cannabics SR capsules. The positive responses and high satisfaction level of patients and doctors with this cannabis based therapy option has been overwhelming.”

For more information, visit www.cannabics.com

Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com

 

 

 

qualitystocks
10/1/2014 1:16:13 PM

Cannabics Pharmaceuticals, Inc. (CNBX) is “One to Watch”

Cannabics Pharmaceuticals was founded in 2012 by a group of molecular biology, cancer therapy and pharmacology researchers who recognized the potential of cannabinoid-based therapies for debilitating and incurable ailments. Through the course of its research, the company’s pharmacology team has amassed valuable knowledge in the development of advanced delivery systems for active cannabinoids that provide improved treatment options for patients wishing to utilize the unique medical properties of the cannabis plant.

Leveraging this expertise and knowledge, Cannabics Pharmaceuticals has created a wide range of solutions for standardized, reproducible and easily administered medical cannabis therapies. The company’s flagship product, Cannabics SR, is a sustained release medical cannabis capsule that contains a pure extract of cannabinoids derived from select cannabis strains, embedded in a sophisticated lipid based formulation. The excipients of the proprietary sustained release formulation are all certified food-grade ingredients, free of artificial additives or chemical substances.

Cannabics SR capsules have been shown to provide beneficial therapeutic effects for 10-12 hours within the therapeutic window. To date, more than 100 patients in Israel – the majority of them oncology patients – have been treated with Cannabics SR capsules as a palliative therapy.

Cannabics Pharmaceuticals intends to launch a series of clinical studies of Cannabics SR capsules in leading medical centers in Israel where the company’s R&D division is strategically located. The results, combined with the superior pharmacokinetic profile of the Cannabics SR formulation, will be the key advantage of Cannabics Pharmaceuticals’ products over competing medical cannabis products available in the market.

Pivoting off of the trial data, the company plans to market Cannabics SR capsules under the current medical cannabis regulations in the United States, Europe and Israel. The company has recently achieved Good Manufacturing Practices (GMP) capabilities, thus ranking its products among a very limited number of medical cannabis products available in the US market that are manufactured according to these high-quality standards.

Cannabics Pharmaceuticals’ proprietary technologies are developed in certified laboratories and are licensed to certified manufacturers and distributors with adequate licenses in their local territories. Cannabics Pharmaceuticals itself does not manufacture, distribute, dispense or possess any controlled substances, including cannabis and cannabis-based preparations.

Co-founders Dr. Zohar Koren (CEO) and Dr. Eyal Ballan (CTO) guide the company’s operations with vast experience in medical research and pharmaceutical product development. Under their leadership, Cannabics Pharmaceuticals continues to develop its genetic and phenotipic database to provide superior treatments for incapacitating ailments for which there is no cure, building a pipeline of additional cannabis-based products for indications such as cancer, neuropathic pain, inflammatory bowel disease, post trauma stress syndrome, CNS degenerative disorders and more.

For more information, visit www.cannabics.com

Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com

 

 

 

qualitystocks
10/6/2014 3:01:30 PM

Cannabics Pharmaceuticals Inc. (CNBX) Putting Bio-technology in a Blooming Traditional Industry

It’s common knowledge that law tends to trail technology and social movements, sometimes by years, sometimes by decades. The process of getting new ideas codified in clear and workable legislation can be a long and arduous path, often spotted with periods of contradictory or inconsistently enforced regulations. Nevertheless, after a certain amount of trial and error, the dust eventually settles, issues get clarified, and real changes can take effect.

The mounting pressure to allow the use of cannabinoids for the palliative treatment of patients with cancer and other diseases has begun to open the door to a multi-billion dollar market in the U.S., also potentially generating billions in tax revenue. The amount of money involved in all this has led to contentious ballot measures at state and city levels throughout the country, with increasing degrees of legalization expected to be pushed through for years to come.

Although the legalization of recreational marijuana is in the sites of various activist groups, by far the most wide-spread support continues to focus on cannabinoids for medical use. And it’s not just for cancer. A number of painful and debilitating diseases are now considered targets for the use of medical cannabis. For example, according to a recent report in silive.com (http://dtn.fm/8HtB), both U.S. senators from New York have called on the Department of Justice to allow for the speed up of the state’s new medical marijuana dispensing program for children experiencing epilepsy and other seizure disorders.

However, in spite of the fact that marijuana has already established itself as a major industry in California and elsewhere, it’s an industry that is still largely unorganized and fragmented. As a result, there remain huge quality and information gaps, a mounting problem for new patients who are used to dealing with the medical establishment. The lack of modern controlled research and product development has hampered progress. Still, for some companies, this has represented a unique opportunity.

Cannabics Pharmaceuticals Inc. has been working to introduce much needed technology and control to the development of cannabinoid based products. Interestingly, the company itself does not manufacture, distribute, or dispense any controlled substances. Rather it develops proprietary technologies that are then licensed for use by certified and governmentally approved manufacturers and distributors. Their goal is the scientific determination of efficacy for various cannabis strains as therapies for specific indications, along with the best administration routes for active cannabinoids, something severely lacking in the U.S. medical cannabis industry since regulation essentially halted it nearly a century ago.

The company has already formulated carefully-researched Cannabics SR Capsules targeting cancer patients, and has achieved Good Manufacturing Practices (GMP) capabilities in preparation for its first clinical study of the capsules. Adhering to these practices ranks the company’s products among a very limited number of medical cannabis products available in the U.S. market that are manufactured according to GMP standards.

For more information, visit www.cannabics.com

Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com

 

 

 

qualitystocks
10/16/2014 1:45:53 PM

Cannabics Pharmaceuticals, Inc. (CNBX) Offers Innovative Palliative Treatment for Cancer Sufferers

The medical marijuana (MMJ) space has been growing by leaps and bounds in recent years as the federal government continues easing their Schedule I enforcement regarding cannabis, allowing states to set the framework on their own so long as it abides by the dictates of federal guidance. This practice has led to 23 states and D.C. adopting some form of MMJ legislation.

One of the leading vectors within the MMJ space has been the extremely positive results that have continued to crop up as a result of testing cannabis therapies against a host of conditions. Of particular note are a variety of chronic/neuropathic pain conditions that can be treated with MMJ, with palliative therapy in cancer patients being one of the most well-known uses and the benefits over typical analgesics like opiates and NSAIDS (non-steroidal anti-inflammatory drugs) continuing to become apparent, especially considering the well-documented appetite simulative effects that are key for conditions like inflammatory bowel disease. Such results have big pharma understandably concerned, as more and more of the pain control market is eaten up each year by MMJ, and the rising star of cannabidiol (CBD) is one of the biggest threats to the pharmaceutical status quo.

CBD is a non-psychoactive compound derived from cannabis which is potentially quite potent depending on the particular strain of cannabis used, even despite the fact that a given strain may be very low in THC (the psychoactive component), as is the case with the now-famous Charlotte’s Web strain used to treat the cripplingly severe seizures of Charlotte Figi, a seven-year-old girl with Dravet Syndrome (a rare and catastrophic form of intractable epilepsy), which caused her to experience multiple seizures per day. The Charlotte’s Web strain has almost no psychoactive effects, yet delivers powerful seizure control capabilities, detailing further the efficacy of MMJ treatment in general for neurological disorders well beyond neuropathic pain.

The anti-cancer prospects are even more tantalizing and with a large body of studies now built up showing broad-spectrum impact in oncology, consumers are getting wise to the potential of THC and CBD rich MMJ treatments. Marijuana Business Daily sees the domestic MMJ space growing to around $8.2B in the next four years, a staggering rise of 200% over the roughly $2.34B estimated by ArcView for this year. With obvious heavy-hitters like GW Pharmaceuticals (NASDAQ: GWPH) already seeing serious upside on their Multiple Sclerosis drug, Sativex®, and a much wider space rapidly emerging that features everything from sodas and edibles, to vaporizer pens and nutraceuticals, the MMJ sector continues to attract new players and investors alike.

One of these players, Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), is currently developing a wide range of indication specific medical cannabis therapies for various indications. The company’s flagship product, Cannabics SR, which is designed as a palliative care therapy for oncology patients, has attained GMP (good manufacturing practices) manufacturing capabilities last month, thus placing CNBX’s proprietary product among a select few market-ready offerings to date with this designation for quality. Cannabics SR is based on a sophisticated lipid based formulation that has shown in observational studies the ability provide 10-12 hours of steady state beneficial therapeutic effects for oncology patients upon a single oral administration.

The company continues to advance a broad-spectrum pipeline of offerings and looks to be one of the first to commercialize a range of clinically tested cannabis-based products designed for specific indications. The company is preparing to launch a series of clinical studies at leading medical centers in Israel where their R&D division is strategically located. Over 100 patients have already been treated in Israel with Cannabics SR according to the company’s latest report and they have achieved high levels of satisfaction from both patients and doctors.

More on Cannabics Pharmaceuticals is available at www.cannabics.com

Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com